Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)

NCT00000923 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00000923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00000923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Not applicable
Overall status
Completed
Start date
Not reported
Completion date
August 31, 2004
Enrollment
110
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections